EVGN Live-Signale | Maximieren Sie Profite mit Getagraph.com

Live Chart Being Loaded With Signals

Commentary (29 Apr 2024 @ 22:00):

Stats
Tagesvolumen	34 423.00
Durchschnittsvolumen	158 719
Marktkapitalisierung	32.89M
EPS	$0 ( 2024-03-07 )
Nächstes Ertragsdatum	( $-0.0700 ) 2024-05-16
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.250
ATR14	$0.0100 (1.54%)

Volumen Korrelation

Lang: -0.11 (neutral)

Kurz: 0.90 (strong)

Signal:(53.234) Same movement expected

Evogene Ltd Korrelation

10 Am meisten positiv korreliert
PSTX	0.926
AVDX	0.922
MULN	0.913
NESR	0.909
PRAX	0.907
OM	0.901
ENTA	0.901
UBFO	0.9
MPAA	0.899
TKNO	0.894

10 Am meisten negativ korreliert
EPZM	-0.922
CNCE	-0.906
XOG	-0.898
LMNL	-0.869
TLMD	-0.868
TYHT	-0.867
RESN	-0.862
SIVBP	-0.85
CNST	-0.849
FIZZ	-0.847

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

Evogene Ltd Korrelation - Währung/Rohstoff

-0.12
( neutral )

-0.35
( neutral )

0.00
( neutral )

-0.69
( moderate negative )

Evogene Ltd Finanzdaten

Annual	2023
Umsatz:	$5.64M
Bruttogewinn:	$1.40M (24.80 %)
EPS:	$-0.520

FY	2023
Umsatz:	$5.64M
Bruttogewinn:	$1.40M (24.80 %)
EPS:	$-0.520

FY	2022
Umsatz:	$1.68M
Bruttogewinn:	$766 000 (45.73 %)
EPS:	$-0.720

FY	2021
Umsatz:	$930 000
Bruttogewinn:	$163 000 (17.53 %)
EPS:	$-0.690

Financial Reports:

No articles found.

Evogene Ltd

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in multiple life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The CPB platform, incorporating a deep understanding of biology leveraged through big data and artificial intelligence, designed to computationally discover and uniquely guide the development of life-science products based on microbes, small molecules, and genetic elements. The company operates through three segments: Agriculture, Human Health, and Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. Its products focus on various crops, such as corn, soybean, wheat, rice, and cotton. The Industrial Applications segment develops enhanced castor bean seeds to serve as a feedstock source for other industrial uses. The Human Health segment discovers and develops human microbiome-based therapeutics for the treatment of immuno-oncology, GI related disorders, and antimicrobial resistance organisms. The company also provides medical cannabis products. It operates in the United States, Israel, Brazil, and internationally. The company has strategic collaborations and licensing agreements with agricultural companies, such as BASF SE, Corteva, and Bayer; and through its subsidiary, Canonic Ltd., has a collaboration agreement with Cannbit Ltd. for the development of novel medical cannabis products. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel.